In the last trading session, 2.31 million AIM ImmunoTech Inc (AMEX:AIM) shares changed hands as the company’s beta touched 0.96. With the company’s per share price at $0.09 changed hands at -$0.03 or -19.37% during last session, the market valuation stood at $6.86M. AIM’s last price was a discount, traded about -588.89% off its 52-week high of $0.62. The share price had its 52-week low at $0.11, which suggests the last value was -22.22% down since then. When we look at AIM ImmunoTech Inc’s average trading volume, we note the 10-day average is 0.5 million shares, with the 3-month average coming to 1.01 million.
Analysts gave the AIM ImmunoTech Inc (AIM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AIM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. AIM ImmunoTech Inc’s EPS for the current quarter is expected to be -0.09.
AIM ImmunoTech Inc (AMEX:AIM) trade information
Instantly AIM was in red as seen at the end of in last trading. With action -21.57%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -52.07%, with the 5-day performance at -21.57% in the red. However, in the 30-day time frame, AIM ImmunoTech Inc (AMEX:AIM) is -29.34% down. Looking at the short shares, we see there were 3.17 million shares sold at short interest cover period of 3.1 days.
AIM ImmunoTech Inc (AIM) estimates and forecasts
Year-over-year growth is forecast to reach 1,429.41% up from the last financial year.
1 analysts are of the opinion that AIM ImmunoTech Inc’s revenue for the current quarter will be 100k. The company’s revenue for the corresponding quarters a year ago was 40k and 50k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.59%.
AIM Dividends
AIM ImmunoTech Inc is expected to release its next quarterly earnings report on 2025-Mar-26.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.99% of AIM ImmunoTech Inc shares while 11.06% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 11.89%. There are 11.06% institutions holding the AIM ImmunoTech Inc stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 7.718% of the shares, roughly 4.08 million AIM shares worth $1.52 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.021% or 1.99 million shares worth $0.74 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 1.31 shares estimated at $0.12 million under it, the former controlled 1.81% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.86% of the shares, roughly 620.23 shares worth around $58859.0.
